About the Company
We do not have any company description for SpringWorks Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on SpringWorks Therapeutics, Inc.
Merck's SpringWorks Therapeutics gets nod for Ogsiveo from European Commission for adults with Desmoid Tumors
Stamford: SpringWorks Therapeutics, Inc., a healthcare company of Merck, has received marketing authorization from the ...
SpringWorks Therapeutics, Inc.: European Commission Grants Approval of OGSIVEO (nirogacestat) for the Treatment of Adults with Desmoid Tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., ...
SpringWorks Therapeutics: Surging On Ogsiveo Approval, Long-Term ...
SpringWorks Therapeutics, Inc. (SWTX), the Stamford, Conn.,-based biotech that launched its initial public offering ("IPO") in September 2019, raising ~$186 via the issuance of 10.35m shares ...
SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer ...
--SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that ...
SpringWorks Therapeutics Announces Proposed Public Offering of ... - Nasdaq
--SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of ...
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights ...
SpringWorks Therapeutics Inc (NASDAQ:SWTX) reported $49.3 million in net product revenue for the third quarter, representing a 23% growth quarter over quarter. The company has successfully ...
Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 ...
Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for ...
Norges Bank Invests $6.74 Million in SpringWorks Therapeutics, Inc ...
SpringWorks Therapeutics, Inc. has a 1 year low of $28.21 and a 1 year high of $62.00. The stock has a 50-day moving average price of $48.71 and a two-hundred day moving average price of $39.99.
SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results ...
STAMFORD, Conn., Aug. 04, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with ...
SpringWorks Therapeutics Inc Ordinary Shares SWTX - Morningstar
SpringWorks Therapeutics Inc Ordinary Shares SWTX Stock XNAS Rating as of Apr 17, 2025 Download PDF Summary Chart News Price vs Fair Value Sustainability Trailing Returns Key Metrics Financials ...
SpringWorks Therapeutics Announces Clinical ... - Markets Insider
STAMFORD, Conn., Sept. 14, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for ...
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Consensus Rating of ...
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) has received a consensus recommendation of “Hold” from the eight brokerages that are covering the stock, MarketBeat.com reports.
Similar Companies
Loading the latest forecasts...